Ovarian clear cell carcinoma accounts for approximately five to ten percent of American ovarian cancer cases and about 20 percent of cases in Asia, ranking second as the cause of death from ovarian cancer. People with the clear cell subtype typically do not respond well to platinum-based chemotherapy, leaving limited therapeutic options for these patients.
The research by scientists at The Wistar Institute and published online in the journal Nature Cell Biology, demonstrates how a mutation in ovarian clear cell carcinoma can be exploited to design a targeted treatment.
According to the announcement from The Wishtar Institute, “conventional chemotherapy treatments have proven an ineffective means of treating this group of ovarian cancer patients, meaning that alternative strategies based on a person’s genetic makeup must be explored,” said Rugang Zhang, Ph.D., professor and co-program leader in Wistar’s Gene Expression and Regulation Program and corresponding author of the study. “Therapeutic approaches based on the ARID1A mutation have the potential to revolutionize the way we treat these patients.”
Read more about the research and about JKTG’s cancer research collaborative at Wistar.
Featured news
Ted’s Take: Ted’s Take: Coalescing or Convergent Thinking
I’d like to introduce the concept that coalescing or “convergent thinking” may be detrimental within an organizational setting. By this, I mean that individuals working in the same or similar space often tend to think similar thoughts.
Ted’s Take: We all have a role to play in climate change research
One would think that research about climate issue is one area that people would come together and commit to doing it right – collaboratively, transparently and without ego.
Why aren’t we talking about this? Key questions raised by the Medicare Trustees Report
The Medicare Trust Fund (TF) Annual Trustees report on solvency drives much of the discussion about Medicare payments. Therefore, it’s important and appropriate to understand the underpinnings of the report in order to best understand and engage in the discussion.
Jayne Koskinas Ted Giovanis
Foundation for Health and Policy
PO Box 130
Highland, Maryland 20777
Media contact: 202.548.0133